Endoscopic Factors Predisposing to Rebleeding Following Endoscopic Hemostasis in Bleeding Peptic Ulcers

Background and Study Aims: Various clinical and endoscopic factors have been proposed and used as predictors of endoscopic treatment failure in bleeding peptic ulcers. Recently, several endoscopic factors have been considered to be more significant than various clinical factors, except for shock. Detailed knowledge of which endoscopic factors can be classified as predictors of rebleeding following endoscopic hemostasis is needed. This study describes newly defined endoscopic variables and evaluates their usefulness as predictors of endoscopic treatment failure.

Patients and Methods: Between January 1996 and April 1999, diagnostic and therapeutic endoscopies were carried out in 143 patients with active bleeding peptic ulcers. Nine clinical and eight endoscopic variables were studied. Endoscopic factors were classified by three types of stigmata bleeding, 14 locations, two ulcer sizes, three ulcer bases, three visible vessel colors, two ulcer depths, two margin shapes, and three endoscopic treatment methods (injection, hemoclipping, and combination).

Results: 36 patients experienced rebleeding (25.2 %), 11 patients needed operations (7.7 %) and five deaths occurred (3.5 %). In univariate analysis, rebleeding was significantly related to: i) presence of spurting activity (odds ratio [OR] = 4.91, P = 0.006), ii) ulcer size larger than 2 cm (OR = 2.78, P = 0.017); and iii) location in stomach (OR = 2.81, P = 0.026). Clinical variables including age, shock, and initial hemoglobin levels were not significantly related to rebleeding. In multiple logistic regression using selected significant variables, presence of spurting activity remained a significant independent predictor of rebleeding (adjusted OR = 6.48, P = 0.003).

Conclusion: Our data support the hypothesis that endoscopic factors are more important than clinical ones when predicting rebleeding of peptic ulcers. Based on statistical analysis of risk factors, the ulcers most likely to rebleed after endoscopic therapy are those which are located in the stomach, are greater than 2 cm in diameter and exhibit oozing or spurting of blood.

References

• 1 Balanzo J, Sainz S, Such J, et al. Endoscopic hemostasis by local injection of epinephrine and polidocanol in bleeding ulcer; a prospective randomized trial.  Endoscopy. 1988;  20 289-291
• 2 Panes J, Viver J, Forme M, et al. Controlled trial of endoscopic sclerosis in bleeding peptic ulcers.  Lancet. 1987;  2 1292-1294
• 3 Chung S CS, Leung J WC, Steele R JC, et al. Endoscopic injection of adrenaline for actively bleeding ulcers: a randomized trial.  Br Med J. 1988;  296 1631-1633
• 4 Oxner R BG, Simmonds N J, Gertner D J, et al. Controlled trial of endoscopic injection treatment for bleeding from peptic ulcers with visible vessels.  Lancet. 1992;  339 966-968
• 5 Moreto M, Zaballa M, Suarez M J, et al. Endoscopic local injection of ethanolamine oleate and thrombin as an effective treatment for bleeding duodenal ulcer: a controlled trial.  Gut. 1992;  33 456-459
• 6 Swain C P, Kirkham J S, Salmon P R, et al. Controlled trial of Nd-YAG laser photocoagulation in bleeding peptic ulcers.  Lancet. 1986;  1 1113-1117
• 7 Laine L. Multipolar electrocoagulation in the treatment of active upper gastrointestinal hemorrhage: a prospective controlled trial.  N Engl J Med. 1987;  316 1613-1617
• 8 Brullet E, Campo R, Calvet X, et al. Factors related to the failure of endoscopic injection therapy for bleeding gastric ulcer.  Gut. 1996;  39 155-158
• 9 Brullet E, Calvet X, Campo R, et al. Factors predicting failure of injection therapy in bleeding duodenal ulcer.  Gastrointest Endosc. 1996;  43 111-116
• 10 Lin H J, Lee F Y, Tsasi Y T, et al. What kind of non-bleeding visible vessel in a peptic ulcer needs aggressive therapy?.  Endoscopy. 1988;  20 8-11
• 11 Villanueva C, Balanzo J, Espinós J C, et al. Prediction of therapeutic failure in patients with bleeding peptic ulcer treated with endoscopic injection.  Dig Dis Sci. 1993;  38 2062-2070
• 12 Saeed Z A, Ramirez F C, Hepps K S, Cole R A, Graham D Y. Prospective validation of Baylor bleeding scoring for predicting the likelihood of rebleeding after endoscopic hemostasis of peptic ulcer.  Gastrointest Endosc. 1995;  41 561-565
• 13 Choudari C P, Rajgopal C, Elton R A, Palmer K R. Failures of endoscopic therapy for bleeding peptic ulcer: an analysis of risk factors.  Am J Gastroenterol. 1994;  89 1968-1972
• 14 Swain C P, Salmon P R, Northfield T C. Does ulcer position influence presentation or prognosis of acute gastrointestinal bleeding?.  Gut. 1986;  27 A632
• 15 Freeman M L, Cass O W, Peine C J, Onstad G R. The non-bleeding visible vessel versus the sentinel clot: natural history and risk of rebleeding.  Gastrointest Endosc. 1993;  39 359-366
• 16 Chung I K, Hahm J S, Kim H S, et al. Comparison of the hemostatic efficacy of the endoscopic hemoclip method with hypertonic saline-epinephrine injection and a combination of the two for the management of bleeding peptic ulcers.  Gastrointest Endosc. 1999;  49 13-18
• 17 Lin H J, Tseng G Y, Lo W C, et al. Predictive factors for rebleeding in patients with peptic ulcer bleeding after multipolar electrocoagulation: a retrospective analysis.  J Clin Gastroenterol. 1998;  26 113-116
• 18 Lin H J, Perng C L, Lee F Y, et al. Clinical courses and predictors for rebleeding in patient with peptic ulcers and non-bleeding visible vessels - a prospective study.  Gut. 1994;  35 1389-1393
• 19 Lau J YW, Chung S CS, Leung J W, et al. The evolution of stigmata of hemorrhage in bleeding peptic ulcers: a sequential endoscopic study.  Endoscopy. 1999;  30 513-518
• 20 Johnston J H. Endoscopic risk factors for bleeding peptic ulcer.  Gastrointest Endosc. 1990;  36 S16-S20
• 21 Green F W, Kaplan M M, Curtis L E, Levine P H. Effect of acid and pepsin on blood coagulation and platelet aggregation.  Gastroenterology. 1978;  74 38-43
• 22 Collier D SJ, Crampton J, Everett W G. Acute hemorrhagic gastritis controlled by omeprazole.  Lancet. 1989;  1 776
• 23 Brunner G, Chang J. Intravenous therapy with high doses of ranitidine and omeprazole in critically ill patients with bleeding peptic ulcerations of the upper intestinal tract: an open randomized controlled trial.  Digestion. 1990;  45 217-219
• 24 O'Leary M J, Park G R. Intravenous omeprazole in upper gastrointestinal hemorrhage in critically ill patients.  Digestion. 1991;  48 59-60
• 25 Muckadell O BSD, Havelund T, Harling H, et al. Effect of omeprazole on the outcome of endoscopically treated bleeding peptic ulcers. Randomized double-blind placebo-controlled multicentre study (see comments).  Scand J Gastroenterol. 1997;  32 320-327
• 26 Villanueva C, Balanzo J, Toras X, et al. Omeprazole versus ranitidine as adjunct therapy to endoscopic injection in actively bleeding ulcers: a prospective and randomized study.  Endoscopy. 1995;  27 308-312
• 27 Saeed Z A, Winchester C B, Michaletz P A, et al. A scoring system to predict rebleeding after endoscopic therapy of nonvariceal upper gastrointestinal hemorrhage, with a comparison of heat probe and ethanol injection.  Am J Gastroenterol. 1993;  88 1842-1849
• 28 Pimple W, Boeckl O, Waclawiczek H W, Heinerman M. Estimation of the mortality rates of patients with severe gastroduodenal hemorrhage with the aid of a new scoring system.  Endoscopy. 1987;  19 101-106
• 29 Provenzale D, Sandler R S, Wood D R, et al. Development of a scoring system to predict mortality from upper gastrointestinal bleeding.  Am J Med Sci. 1987;  294 26-32
• 30 Clamp S E, Morgan A G, Kotwai M R, et al. Use of a multinational survey to provide clinical guidelines for upper gastrointestinal bleeding in developing countries.  Scand J Gastroenterol. 1988;  23 63-69
• 31 Schien M, Gecelter G. APACHE II score in massive upper gastrointestinal haemorrhage from peptic ulcer: prognostic value and potential clinical applications.  Br J Surg. 1989;  76 733-736